Phalanx Biotech Group is a Taiwan-based genetic testing company offering complete solutions from product design and manufacturing to clinical services and data analysis. Established in 2002, Phalanx originated from a national biotech initiative and has since expanded its presence across Asia and the U.S., with headquarters in Hsinchu Biomedical Science Park. We specialize in high-quality genetic testing platforms, including chromosomal microarrays, DNA methylation assays, and next-generation sequencing (NGS). Our flagship CytoOneArray® is widely used in prenatal and pediatric diagnostics, and was featured by the Discovery Channel for its role in identifying developmental delays. We also offer MPap®, a TFDA-approved, non-invasive test for early detection of endometrial cancer—designed to meet the growing demand for less-invasive women's health solutions. Our portfolio covers reproductive health, oncology, and personalized health risk screening, such as NIPT, PGT-A, obesity risk panels, and chronic disease assessments. All tests are supported by robust bioinformatics, automated analysis, and clear reporting for healthcare providers and end users. With ISO 13485, ISO/IEC 17025, and GMP-certified facilities, Phalanx ensures high manufacturing standards and scalability to meet global demands. Our team welcomes collaboration with international distributors, laboratories, and healthcare providers who seek innovative, reliable, and cost-effective genetic testing solutions. If you're looking to expand your portfolio with advanced genomic diagnostics—let's connect and explore partnership opportunities.